OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
IMPZY
Implanet SA
Implanet announces its 2017 financial calendar
Bordeaux, Boston, December 19, 2016: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, announced today its schedule for the publication of financial information for 2017.
|
Event |
Dates* |
|
2016 Full-Year Sales |
January 16, 2017 |
|
2016 Full-Year Results |
March 28, 2017 |
|
2017 First-Quarter Sales |
April 18,
2017 |
|
Annual General Meeting |
May 23, 2017 |
|
2017 First-Half Sales |
July 18, 2017 |
|
2017 First-Half Results |
September 19, 2017 |
|
2017 Third-Quarter Sales |
October 17, 2017 |
(*): Press releases are published before market opens. Subject to
modification.
DISCLAIMER
This press release contains forward-looking
statements related to Implanet and its activities. Implanet estimates that
these forward-looking are based on reasonable assumptions. No guarantee is
given as to these forecasts being achieved, which are subject to risks,
including those described in Implanet Reference Document registered with the
French Autorité des marchés financiers (a copy of which is available on www.implanet-invest.com), and to the development of economic
conditions, the financial markets and the markets in which Implanet operates.
Forward-looking statements included in this press release are also subject to
risks unknown for Implanet or not considered by Implanet as significant as of
today. The Company's future performance, the Company’s financial position,
results, cash-flows and developments in the sector may differ materially due to
the realization of one of those risk factors.
About IMPLANET
Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for orthopedic
surgery. Its flagship product, the JAZZ latest-generation implant, aims to
treat spinal pathologies requiring vertebral fusion surgery. Protected by four
families of international patents, JAZZ has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United States and
the CE mark. IMPLANET employs 48 people and recorded 2015 sales of €6.7
million. For further information, please visit www.implanet.com
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the
Euronext™ regulated market in Paris.
IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (5) 57 99 55 55
Alpha Bronze
US – Investor Relations
Pascal Nigen
Tel.: +1 (917) 385-2160
NewCap
Investor Relations – France
Florent Alba
Tel.: +33 (5) 57 99 55 55
